Obesity, metabolic health, and history of Cytomegalovirus infection in the general population

This item was submitted to Loughborough University’s Institutional Repository by the/an author.

Citation: HAMER, M., BATTY, G.D. and KIVIMAKI, M., 2016. Obesity, metabolic health, and history of Cytomegalovirus infection in the general population. The Journal of Clinical Endocrinology & Metabolism, In press.

Additional Information:

- This paper was accepted for publication in the journal Journal of Clinical Endocrinology and Metabolism and the definitive published version is available at http://dx.doi.org/10.1210/jc.2015-4208

Metadata Record: https://dspace.lboro.ac.uk/2134/20369

Version: Accepted for publication

Publisher: © Endocrine Society

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Please cite the published version.
Obesity, Metabolic Health, and History of Cytomegalovirus Infection in the General Population

Mark Hamer,1,2,3 G. David Batty,3 Mika Kivimäki3

1 School of Sport, Exercise & Health Sciences, Loughborough University; 2NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, Leicester, UK; 3Department of Epidemiology & Public Health, University College London, London, UK.

Context: Common community-acquired infections, such as cytomegalovirus (CMV), may contribute to the development of obesity and metabolic dysfunction, but empirical evidence is scarce.

Objective: We examined the associations between CMV, obesity and metabolic characteristics in a large, general population-based sample of adults.

Design and setting: An observational study in community dwelling adults from the general population, ‘Understanding Society – the UK Household Longitudinal Study’.

Participants: 9,517 men and women (aged 52.4 ± 16.4 yrs; 55.3% female).

Measures: CMV infection was measured using Immunoglobulin G (IgG) from serum. Obesity was defined as body mass index ≥30 kg/m². Based on blood pressure, HDL-cholesterol, triglycerides, glycated haemoglobin A1c, and C-reactive protein, participants were classified as ‘healthy’ (0 or 1 metabolic abnormality) or ‘unhealthy’ (≥2 metabolic abnormalities).

Results: A positive CMV test was recorded in 47.5% of the sample. There was no association between CMV and obesity. Of the individual metabolic risk factors, CMV was positively associated with glycated haemoglobin and HDL-cholesterol. In combination, only ‘unhealthy non-obese’ participants had modestly increased odds of CMV (odds ratio compared to healthy normal-weight 1.12, 95% confidence interval 1.00 – 1.26) after adjusting for a range of variables. CMV was associated with an increased prevalence of cardiovascular diseases (odds ratio 1.67; 1.07 – 2.60) independently of obesity, metabolic risk factors, and other covariates.

Conclusion: Our findings suggest a weak but statistically significant association between CMV and metabolic dysfunction in non-obese adults. This relationship appears to be masked in the obese, possibly by the effects of excess adiposity on metabolism.

Key words: cytomegalovirus; epidemiology; infection; obesity

Cytomegalovirus (CMV) is one of the most well-characterized infections in humans. This infection is typically acquired in childhood and is lifelong. Although CMV rarely causes symptoms, it has been linked to adverse metabolic characteristics, including obesity (1–4) and factors that accompany this condition, such as impaired glucose control and dyslipidaemia (5–12). These associations are biologically plausible because infection provokes immune responses, such as the release of inflammatory cytokines that have been linked to the etiology of metabolic disorders including diabetes (13). Infection with CMV might also contribute to features of immunosenescence, such as the accumulation of differentiated cytotoxic T cells. Some evidence suggests that the accumulation of these cells could drive an unfavourable metabolic profile (14). In addition, it has been postulated that excess adipose tissue may lead to susceptibility to infections, such as CMV, (2, 4) through influencing a variety of immune...
mediators. However, the adverse effects of excess adiposity on metabolism might also mask any association between CMV and metabolic parameters.

Existing data on obesity, metabolic dysfunction and acquired infections is generally sparse. Most studies have suffered from methodological weaknesses such as small sample sizes (n < 150), (5, 7–8) case-control rather than prospective designs, (5, 7–8, 11) and inadequate adjustment for sociodemographic factors. To the best of our knowledge, no large-scale studies to date have simultaneously examined the associations of CMV with both obesity and metabolic health, controlling for potential confounding factors, such as poor lifestyle and social disadvantage, (12, 15) to evaluate the strength of these associations in the general population and to separate the possible underlying mechanisms. These associations may have important clinical implications as CMV infections, although common, are not routinely subject to screening and treatment is considered only in the rare event the infection is activated and symptomatic.

Materials and Methods

Understanding Society – the UK Household Longitudinal Study (UKHLS) – is a large, longitudinal survey of households in the United Kingdom (England, Scotland, Wales and Northern Ireland). In 2010–2012, participants completed a face-to-face interview and nurse health assessments were conducted approximately five months following completion of the survey interview (16). In brief, in the general population sample there was a 58.6% response for the nurse assessment component and full blood samples were successfully collected in 10 175 participants. Participants gave full informed written consent to participate in the study and ethical approval was obtained from the Ethics Committee of the University of Essex (main survey) and National Research Ethics Service Oxfordshire REC A (nurse health assessment).

Nurse health assessment

Nurses collected anthropometric data (weight, height, waist circumference), blood pressure (BP), and nonfasting blood samples using standard protocols. Body weight was measured using Tanita BF 522 scales without shoes and in light clothing, and height was measured using a Stadiometer with the Frankfurt plane in the horizontal position. Body mass index (BMI) was calculated as weight (kilograms)/height (meters) squared. Waist circumference was recorded twice using measuring tape midway between the iliac crest and lower rib. An average of the first two measurements was used provided these differed by no more than 3 cm; otherwise a third reading was taken and the two closest results utilized. Systolic and diastolic BP was measured with an Omron HEM-907 BP monitor three times in the sitting position after 5-minute rest between each reading. The initial reading was discarded and an average of the second and third BP recordings was used for the present analyses. All respondents were eligible to give blood except pregnant women, individuals who volunteered that they are HIV positive or had hepatitis B or C, persons with clotting or bleeding disorder such as hemophilia, or those with a self-declared low platelet count. Additionally, people who had ever had a fit, or those taking anticoagulation medication (eg, warfarin) were also excluded. Blood samples were analyzed for C-reactive protein (CRP), high density lipoprotein (HDL) cholesterol, triglycerides, and glycosylated hemoglobin (HbA1c). Detailed information on the technicalities of the blood analysis have been described elsewhere (17).

Measurement of Cytomegalovirus (CMV) antibodies

Immunoglobulin G (IgG) and IgM were measured from serum samples with an electrochemiluminescent immunoassay (Roche E170 analyzer). Interassay intra-assay coefficients of variation were acceptable, less than 4%. A positive CMV IgG result indicates a CMV infection at some point in time, while a negative CMV IgG indicates that the participant has never been exposed to, or been infected with, CMV. A positive Immunoglobulin M (IgM) indicates a recent or current infection. Indeterminate CMV occurs during current or acute infection or may be due to nonspecific binding. For those people who had a positive IgM test or whose result was indeterminate, an additional test was performed to confirm recent CMV infection. This confirmatory assay was an avidity test on the Mini VIDAS immunoassay analyzer.

Covariables

Health-related questions included cigarette smoking (current; previous; nonsmoker), the frequency of participation in sports and exercise (more than three times per week; 1–3 times per week; once per month or less; never), and the frequency of alcohol intake (at least 5–6/wk; 1–4/wk; monthly; rarely never). Participants were also asked to state their highest educational attainment (Degree; A-level/GCSE; other; none) and to rate their health (excellent; very good; good; fair; poor).

Statistical analyses

Body mass index was categorised into four groups (normal: from 18.5 to < 25 kg/m²; overweight: from 25 to < 30 kg/m²; obese I: from 30 to < 35 kg/m²; obese II and more severe forms: ≥ 35 kg/m²). Based on existing criteria (18) unhealthy metabolic status was defined as having two or more of the following metabolic risk factors: high BP (systolic/diastolic BP ≥ 130/85 mmHg, or hypertension diagnosis, or use of antihypertensive medication), impaired glycaemic control (HbA1c ≥ 6.0% [42.1 mmol/mol] or doctor’s diagnosed diabetes), systemic inflammation (CRP ≥ 3 mg/l), low HDL cholesterol (< 1.03 mmol/l in men and < 1.30 mmol/l in women), and high triglycerides (≥ 1.7 mmol/l). Participants were then categorized into four groups: ‘healthy nonobese’; ‘unhealthy nonobese’; ‘healthy obese’; and ‘unhealthy obese’.

We calculated odds ratios (OR) and 95% confidence intervals (CI) for the odds of CMV in relation to obesity, metabolic status and their combination. We tested for sex interactions, but as none were present, men and women were pooled in the same analysis. Initially, we adjusted our effect estimates for sex and age (model 1). We further adjusted the models for education, sports and exercise participation, self-rated health, smoking, and alcohol (model 2). Analyses were conducted using SPSS version 22.
Results

The analytic sample comprised 9517 participants (aged 52.4 ± 16.4 yrs; 55.3% female). A positive CMV test was apparent in 47.5% of the sample. Participants testing positive for CMV tended to be older, female, smokers, have no educational qualifications, and poorer self-rated health (Table 1). In logistic regression models mutually adjusted for all variables, per year increase in age (OR; 95% confidence interval (CI): 1.02, 1.01 – 1.03), being female (1.26; 1.16 – 1.38), a smoker (1.21; 1.07 – 1.37), and no qualifications (1.72; 1.46 – 2.02) remained associated with CMV positive status.

There was no association between BMI and CMV (Table 2), nor did we observe any association when using waist circumference as a measure of central obesity (OR per unit increase = 1.00; 0.99 – 1.01, \( P = .94 \)). Metabolic health was associated with the status of CMV in models adjusted for age and sex, although after further adjustments the association was attenuated to the null (Table 2). In analyses that combined obesity and metabolic health, participants defined as “unhealthy nonobese” had increased odds of being CMV positive (Table 2). In further analyses to examine associations between individual metabolic risk factors and CMV we observed significant associations for HbA1C and HDL-cholesterol (Table 3).

We further examined these associations in relation to a clinically meaningful outcome; 105 self-reported physician-diagnosed cases of cardiovascular diseases (CVD) (including congestive heart failure (CHF), angina/myocardial infarction (MI)/coronary heart disease (CHD), and stroke) were reported. In analyses (Table 4) in which we adjust our effect estimates for covariates, CMV was associated with higher odds of CVD (OR = 1.67, 95% CI, 1.07 – 2.60) independently of obesity and metabolic risk factors.

Discussion

Our main finding was an association between CMV and the individual metabolic risk factors of high glycated hemoglobin and low HDL-cholesterol. However, only metabolically ‘unhealthy nonobese’ participants had an increased prevalence of the acquired infection. In contrast, CMV was not associated with metabolic health in obese participants and there was no association between obesity and CMV. In further analyses using a clinical endpoint, CMV was associated with CVD independently of obesity and metabolic risk factors.

Existing data on metabolic health and acquired infections is generally sparse. Most studies have suffered from methodological weaknesses such as small sample sizes \((n < 150)\), (5, 7–8) case-control rather than prospective designs, (5, 7–8, 11) and inadequate adjustment for sociodemographic factors. With over 9000 participants, our study is, to the best of our knowledge, the largest population-based study on CMV in relation to a range of metabolic factors and obesity.

Obesity is thought to influence the immune response that has been hypothesized to increase susceptibility to infections (2, 4). However, the most plausible interpretation of our findings is that the accumulation of viral load and associated immune activation is driving an unfavourable metabolic profile among nonobese. Obesity often precedes metabolic dysfunction, (19) thus in obese participants is likely to be the strongest driver of metabolic
risk and might explain why the ‘unhealthy obese’ were seemingly not at elevated risk of CMV infection in contrast to their nonobese counterparts.

Associations between CMV and metabolic health were attenuated after adjustment for social and lifestyle factors, suggesting these relationships could be part of a causal pathway starting from social determinants of health. This is consistent with findings from a previous population sample of US adults demonstrating that the association between CMV and diabetes was attenuated to the null in models accounting for social and lifestyle factors (12).

CMV was, however, associated with CVD independently of covariates; this is consistent with prior evidence (20). CMV is known to increase experimental atherosclerosis and to modulate vascular-wall activity, (21, 22) thus the association is likely to be independent of adiposity and metabolic dysfunction.

Infection causes immune responses, such as the release of inflammatory cytokines that have been linked to the etiology of metabolic disorders including diabetes (13).

Table 2. Odds ratios (95% confidence interval) for the relation between obesity, metabolic health and history of CMV infection (n = 9517)

<table>
<thead>
<tr>
<th></th>
<th>CASES/N</th>
<th>Model 1 OR (95% CI)</th>
<th>Model 2 OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Obesity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (18.5 to &lt;25 kg/m²)</td>
<td>1198/2679</td>
<td>1.0 (Ref)</td>
<td>1.0 (Ref)</td>
</tr>
<tr>
<td>Overweight (25 to &lt; 30 kg/m²)</td>
<td>1871/3893</td>
<td>1.02 (0.92 – 1.13)</td>
<td>1.03 (0.93 – 1.15)</td>
</tr>
<tr>
<td>Obese I (30 to &lt;35 kg/m²)</td>
<td>976/1957</td>
<td>1.08 (0.95 – 1.22)</td>
<td>1.06 (0.93 – 1.20)</td>
</tr>
<tr>
<td>Obese II (≥35 kg/m²)</td>
<td>499/993</td>
<td>1.12 (0.96 – 1.30)</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>p-linear trend</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metabolic health?</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy (0 or 1 risk factor)</td>
<td>2658/5956</td>
<td>1.0 (Ref)</td>
<td>1.0 (Ref)</td>
</tr>
<tr>
<td>Unhealthy (&gt;1 risk factor)</td>
<td>1891/3584</td>
<td>1.15 (1.05 – 1.25)</td>
<td>1.05 (0.95 – 1.15)</td>
</tr>
<tr>
<td><strong>p-linear trend</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Continuous score</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy non-obese</td>
<td>2105/4785</td>
<td>1.0 (Ref)</td>
<td>1.0 (Ref)</td>
</tr>
<tr>
<td>Unhealthy non-obese</td>
<td>963/1784</td>
<td>1.22 (1.08 – 1.36)</td>
<td>1.12 (1.00 – 1.26)</td>
</tr>
<tr>
<td>Healthy Obese</td>
<td>546/1151</td>
<td>1.13 (0.99 – 1.29)</td>
<td>1.11 (0.97 – 1.27)</td>
</tr>
<tr>
<td>Unhealthy Obese</td>
<td>927/1797</td>
<td>1.14 (1.02 – 1.28)</td>
<td>1.04 (0.92 – 1.17)</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age and sex
Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, smoking, alcohol.

defined from: High blood pressure (clinic BP ≥130/85 mmHg, or hypertension diagnosis, or use of anti-hypertensive medication), impaired glycaemic control (HbA1c ≥ 6.0% or doctor’s diagnosed diabetes), systemic inflammation (C-reactive protein ≥ 3 mg/liter), low HDL cholesterol (<1.03 mmol/liter in men and <1.30 mmol/liter in women), and high triacylglycerol (≥1.7 mmol/liter).

Table 3. Odds ratios (95% confidence interval) for the relation between individual metabolic risk factors and CMV infection

<table>
<thead>
<tr>
<th>Risk factor (per standard deviation increase)†</th>
<th>Model 1 (OR, 95% CI)</th>
<th>Model 2 (OR, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (8.0 mmol/mol)</td>
<td>1.08 (1.03 – 1.13)</td>
<td>1.01 (1.00 – 1.02)</td>
</tr>
<tr>
<td>HDL-Cholesterol (0.46 mmol/liter)</td>
<td>0.91 (0.87 – 0.95)</td>
<td>0.80 (0.71 – 0.90)</td>
</tr>
<tr>
<td>Triglycerides (1.10 mmol/liter)</td>
<td>1.03 (0.98 – 1.08)</td>
<td>0.99 (0.94 – 1.03)</td>
</tr>
<tr>
<td>C-Reactive Protein (6.75 mg/liter)</td>
<td>1.02 (0.99 – 1.07)</td>
<td>1.00 (0.99 – 1.02)</td>
</tr>
<tr>
<td>Systolic Blood Pressure (16.3 mmHg)</td>
<td>0.95 (0.81 – 1.12)</td>
<td>0.94 (0.80 – 1.11)</td>
</tr>
</tbody>
</table>

†a standard deviation increase denoted after variable
Model 1: adjusted for age and sex
Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, smoking, alcohol, BMI, and mutually for other metabolic risk factors.
Interestingly, we found no association between CRP and CMV, but the link with metabolic health was driven by HDL-cholesterol and HbA1C. This suggests mechanisms other than inflammatory response related to innate immunity may primarily drive the association between CMV and metabolic dysfunction. Recent evidence has shown the accumulation of differentiated cytotoxic T cells in CMV positive participants was associated with HbA1C and cholesterol, (14) suggesting a direct role of the immune cells related to the adaptive immune system.

There are several limitations. Firstly this is a cross-sectional study thus we can only speculate on the causality and direction of our findings. Second, our measurement of pathogen infection was based on seropositivity to IgG antibodies, which reflects prior infection, but are not sensitive indicators of current infection or the chronicity of prior infections. Nevertheless, active pathogen infection is unlikely to have influenced our results as recent infection (measured through positive IgM and confirmatory avidity test) was apparent in less than 0.5% of the sample and removal of these participants did not influence the present results (data not shown). Detailed assessments of immune activity were not possible in the present study. An assessment of T cell pattern in participants with positive or negative CMV test would provide further hints as to how CMV infection impacts on immune cell function driving an unfavourable metabolic profile (23).

In summary, we demonstrated no association between obesity and CMV. We identified a weak but statistically significant association between CMV and metabolic dysfunction in nonobese adults, but not in their obese counterparts. We speculate that in the nonobese CMV infection may drive metabolic dysfunction whereas in the obese population excess adiposity is the main cause of metabolic disturbance. As any associations observed with metabolic risk factors were weak, our findings do not justify universal screening of CMV to prevent diabetes, although there appears to be a stronger association between CMV and CVD.

Acknowledgments

Address all correspondence and requests for reprints to: Corresponding author: Mark Hamer, PhD; School of Sport, Exercise, Health Sciences, Loughborough University, LE11 3TU, United Kingdom, E-mail: m.hamer@lboro.ac.uk; phone: +44 (0) 1509 228473.

This work was supported by .

Disclosure Summary: The authors have nothing to disclose.

References


Table 4. Odds ratios (95% confidence interval) for the associations of CMV infection, obesity, metabolic health with cardiovascular disease.

<table>
<thead>
<tr>
<th></th>
<th>CVD cases/N</th>
<th>Model 1 OR (95% CI)</th>
<th>Model 2 OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CMV infection</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>30/4976</td>
<td>1.0 (Ref)</td>
<td>1.0 (Ref)</td>
</tr>
<tr>
<td>Yes</td>
<td>75/4541</td>
<td>1.81 (1.17 – 1.80)</td>
<td>1.67 (1.07 – 2.60)</td>
</tr>
<tr>
<td><strong>Obesity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (18.5 to &lt;25 kg/m²)</td>
<td>11/2679</td>
<td>1.0 (Ref)</td>
<td>1.0 (Ref)</td>
</tr>
<tr>
<td>Overweight (25 to &lt;30 kg/m²)</td>
<td>38/3893</td>
<td>1.60 (0.81 – 3.17)</td>
<td>1.64 (0.82 – 3.28)</td>
</tr>
<tr>
<td>Obese I (30 to &lt;35 kg/m²)</td>
<td>34/1957</td>
<td>2.63 (1.30 – 5.33)</td>
<td>2.35 (1.14 – 4.84)</td>
</tr>
<tr>
<td>Obese II (≥35 kg/m²)</td>
<td>22/993</td>
<td>3.91 (1.81 – 8.42)</td>
<td>2.83 (1.29 – 6.24)</td>
</tr>
<tr>
<td><strong>Metabolic health</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy (0 or 1 risk factor)</td>
<td>32/5956</td>
<td>1.0 (Ref)</td>
<td>1.0 (Ref)</td>
</tr>
<tr>
<td>Unhealthy (&gt;1 risk factor)</td>
<td>73/3584</td>
<td>1.97 (1.26 – 3.08)</td>
<td>1.59 (1.00 – 2.51)</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age, sex, and mutually for CMV, obesity category, or metabolic health.

Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, smoking, alcohol, and mutually for CMV, obesity, or metabolic health.
6. **Virus Type 1 Infection With Type 2 Diabetes.** *Diabetes Care.* 2005; 28:435–436.


